Fig. 1: Overview of the study design.
From: Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients
a High-risk and symptomatic patients who were referred to an EUS procedure were recruited. Blood draws were performed before the procedure. The final annotation by a board-certified physician on the team, based on a full charge review after more than 1 year from blood collection, categorizes patients into 5 groups: benign pancreas, pancreatitis, IPMN, PDAC, and other cancers. b cfRNA sequencing preparations were performed with randomized samples in a blinded manner at the time of sample processing. c Patient composition of the CEDAR (discovery) and BCC (validation) cohorts. Figure created using BioRender (https://biorender.com).
